KAPA
Kairos Pharma, Ltd.
NYSE AmericanUSDEQUITY
DELAYED
Last price
0.27
▼ 0.03 (8.78%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.31
Prev close
0.30
Day high
0.30
Day low
0.29
Volume
110.56K
Market cap
—
P/E (TTM)
—
52W range
0.27 – 2.11
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-14.96%
-13.6%
1M
-2.68%
-6.4%
3M
-47.56%
-50.7%
6M
-47.75%
-58.8%
YTD
-59.15%
-71.4%
1Y
-72.90%
-92.9%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $2.13M | $414.00K | $82.00K | $87.00K | +415.7% |
| Selling, general & admin | $3.28M | $1.77M | $1.47M | $324.00K | +85.2% |
| Total operating expense | $5.57M | $2.34M | $1.71M | $571.00K | +137.8% |
| Operating income | -$5.57M | -$2.34M | -$1.71M | -$571.00K | -137.8% |
| Net interest income | $125.00K | -$859.00K | -$98.00K | -$479.00K | +114.6% |
| Pre-tax income | -$5.45M | -$2.60M | -$1.81M | -$1.05M | -109.3% |
| Net income | -$5.45M | -$2.60M | -$1.81M | -$1.05M | -109.3% |
| Net income to common | -$5.45M | -$2.60M | -$1.81M | -$1.05M | -109.3% |
| Basic EPS | -0.30 | -0.23 | -0.16 | -0.10 | -30.4% |
| Diluted EPS | -0.30 | -0.23 | -0.16 | -0.10 | -30.4% |
| EBIT | -$5.45M | -$2.41M | -$1.71M | -$591.00K | -125.6% |
| EBITDA | -$5.29M | -$2.25M | -$1.55M | -$431.00K | -134.6% |
| Basic shares | 18.43M | 11.36M | 11.22M | 10.84M | +62.3% |
| Diluted shares | 18.43M | 11.36M | 11.22M | 10.84M | +62.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.49M | $1.27M | $93.00K | $437.00K | — | +253.1% |
| Cash & short-term investments | $4.49M | $1.27M | $93.00K | $437.00K | — | +253.1% |
| Total current assets | $5.39M | $4.17M | $101.00K | $437.00K | — | +29.2% |
| Goodwill & intangibles | $62.00K | $222.00K | $382.00K | $542.00K | — | -72.1% |
| Total assets | $6.54M | $5.77M | $965.00K | $1.04M | — | +13.4% |
| Total current liabilities | $199.00K | $992.00K | $2.40M | $1.63M | — | -79.9% |
| Current debt | — | — | — | — | $380.00K | — |
| Long-term debt | — | — | $638.00K | $582.00K | — | — |
| Total debt | — | — | $638.00K | $582.00K | $380.00K | — |
| Total liabilities | $199.00K | $992.00K | $3.04M | $2.21M | — | -79.9% |
| Retained earnings | -$14.26M | -$8.81M | -$6.21M | -$4.40M | — | -61.8% |
| Shareholder equity | $6.34M | $4.78M | -$2.08M | -$1.18M | — | +32.8% |
| Working capital | $5.19M | $3.18M | -$2.30M | -$1.20M | — | +63.3% |
| Net tangible assets | $6.28M | $4.55M | -$2.46M | -$1.72M | — | +37.9% |
| Shares issued | 20.82M | 13.74M | 12.84M | 12.84M | — | +51.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.45M | -$2.60M | -$1.81M | -$1.05M | — | -109.3% |
| Depreciation & amortisation | $160.00K | $160.00K | $160.00K | $160.00K | — | 0.0% |
| Stock-based compensation | — | $218.00K | $0 | $0 | $300.00K | — |
| Change in working capital | -$806.00K | -$1.98M | $764.00K | $129.00K | — | +59.4% |
| Operating cash flow | -$3.44M | -$3.96M | $81.00K | -$353.00K | — | +13.0% |
| Investing cash flow | — | — | — | $0 | -$109.00K | — |
| Financing cash flow | $6.66M | $5.13M | -$425.00K | $717.00K | — | +29.7% |
| Free cash flow | -$3.44M | -$3.96M | $81.00K | -$353.00K | — | +13.0% |
| End cash position | $4.49M | $1.27M | $93.00K | $437.00K | — | +253.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $684.00K | $538.00K | $608.00K | $496.00K | $493.00K | +27.1% |
| Selling, general & admin | $966.00K | $837.00K | $787.00K | $920.00K | $733.00K | +15.4% |
| Total operating expense | $1.69M | $1.42M | $1.44M | $1.46M | $1.27M | +19.4% |
| Operating income | -$1.69M | -$1.42M | -$1.44M | -$1.46M | -$1.27M | -19.4% |
| Net interest income | $36.00K | $50.00K | $37.00K | $34.00K | $4.00K | -28.0% |
| Pre-tax income | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -21.2% |
| Net income | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -21.2% |
| Net income to common | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -21.2% |
| Basic EPS | -0.08 | — | -0.07 | -0.08 | -0.08 | — |
| Diluted EPS | -0.08 | — | -0.07 | -0.08 | -0.08 | — |
| EBIT | -$1.69M | -$1.36M | -$1.40M | -$1.42M | -$1.27M | -23.8% |
| EBITDA | -$1.65M | -$1.32M | -$1.36M | -$1.38M | -$1.23M | -24.5% |
| Basic shares | 21.01M | — | 20.21M | 17.21M | 15.88M | — |
| Diluted shares | 21.01M | — | 20.21M | 17.21M | 15.88M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | -18.2% |
| Cash & short-term investments | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | -18.2% |
| Total current assets | $4.44M | $5.39M | $6.66M | $4.84M | $6.05M | -17.5% |
| Goodwill & intangibles | $22.00K | $62.00K | $102.00K | $142.00K | $182.00K | -64.5% |
| Total assets | $5.74M | $6.54M | $8.07M | $6.67M | $7.94M | -12.2% |
| Total current liabilities | $431.00K | $199.00K | $402.00K | $676.00K | $805.00K | +116.6% |
| Total liabilities | $431.00K | $199.00K | $402.00K | $676.00K | $805.00K | +116.6% |
| Retained earnings | -$15.92M | -$14.26M | -$12.90M | -$11.50M | -$10.08M | -11.6% |
| Shareholder equity | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | -16.2% |
| Working capital | $4.01M | $5.19M | $6.25M | $4.16M | $5.25M | -22.7% |
| Net tangible assets | $5.29M | $6.28M | $7.56M | $5.86M | $6.95M | -15.7% |
| Shares issued | 21.41M | 20.82M | 20.82M | 17.74M | 15.83M | +2.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -21.2% |
| Depreciation & amortisation | $40.00K | $40.00K | $40.00K | $40.00K | $40.00K | 0.0% |
| Change in working capital | $99.00K | -$230.00K | -$210.00K | -$798.00K | $432.00K | +143.0% |
| Operating cash flow | -$1.04M | -$1.08M | -$838.00K | -$805.00K | -$714.00K | +4.4% |
| Financing cash flow | $220.00K | $0 | $3.38M | $223.00K | $3.06M | — |
| Free cash flow | -$1.04M | -$1.08M | -$838.00K | -$805.00K | -$714.00K | +4.4% |
| End cash position | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | -18.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.33
-18.40% from price
SMA 20
0.33
-11.63% from price
SMA 50
0.36
-18.40% from price
SMA 100
0.45
-40.29% from price
SMA 200
0.59
-50.52% from price
EMA 12
0.32
-16.37% from price
EMA 26
0.33
-19.47% from price
EMA 50
0.37
-26.35% from price
RSI (14)
37.7
Neutral
MACD (12,26,9)
-0.01
Hist -0.00
ATR (14)
0.03
9.38% of price
Realised vol 30D
97.9%
Annualised
Bollinger upper
0.39
20, 2σ
Bollinger lower
0.27
20, 2σ
50 / 200 cross
Death
0.36 vs 0.59
Trend bias
Below 200
-50.52%
Risk profile
Beta vs SPY
1.67
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
97.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-85.5%
Peak to trough
Max drawdown 5Y
-89.0%
Peak to trough
ATR 14
0.03
9.38% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Kairos Pharma to Conduct 1-for-7 Reverse Stock Split
MT Newswires · 1d ago
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Business Wire · 1d ago
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Simply Wall St. · 18d ago
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
Simply Wall St. · 31d ago
Kairos Pharma Collaborates With Bayer to Assess Prostate Cancer Treatment Combination
MT Newswires · 31d ago
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Business Wire · 31d ago
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
TMX Newsfile · 38d ago
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Business Wire · 38d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.